The dorsal raphe nucleus (DRN) is the primary source of serotonergic innervation to the forebrain and plays a crucial role in modulating mood, sleep, appetite, and cognitive functions. Serotonergic neurons in the DRN are prominently involved in neurodegenerative diseases, particularly Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). The DRN's extensive projections to cortical and subcortical regions make it a key player in the non-motor symptoms that often precede and accompany these disorders.
The dorsal raphe nucleus (DRN) is the largest serotonergic brain region in the mammalian brain and provides approximately 70-80% of the forebrain's serotonin (5-HT) supply. The DRN is located in the midbrain and contains a heterogeneous population of neurons, including serotonergic projection neurons, GABAergic interneurons, and glutamatergic neurons. This diversity allows the DRN to modulate neural circuits with remarkable specificity. [1]
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000850 | serotonergic neuron |
| Database | ID | Name | Confidence | [2]
|----------|----|------|------------| [3]
| Cell Ontology | CL:0000850 | serotonergic neuron | Exact | [4]
The DRN contains multiple subnuclei with distinct cellular compositions and projection patterns: [5]
The DRN expresses multiple 5-HT receptor subtypes: [6]
Serotonergic dysfunction is a prominent feature of Alzheimer's disease:
The DRN is critically involved in non-motor symptoms of PD:
Serotonergic alterations contribute to psychiatric symptoms in HD:
](/diseases/parkinsons-disease-—-neurodegenerative-movement-disorder
--alzheimers-disease-—-neurodegenerative-dementia
--huntingtons-disease-—-neurodegenerative-disorder
--serotonin-system-—-serotonin-signaling-pathways
--basal-ganglia-circuitry-—-motor-control-circuits
--depression-in-neurodegeneration-—-mood-disorders)## External Links
The study of Dorsal Raphe Serotonergic Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Belmaker RH, Agam G. (2008). Major depressive disorder. New England Journal of Medicine, 358(1): 55-68. 2008. ↩︎
Paoletti P, et al. (2020). Serotonergic dysfunction in Parkinson's disease. Journal of Neural Transmission, 127(5): 751-762. 2020. ↩︎
Meltzer CC, et al. (2004). Serotonin 5-HT1A receptor binding and depression in Alzheimer's disease. Journal of Neurology, Neurosurgery & Psychiatry*, 75(4): 631-636. 2004. ↩︎
Kasper S, McEwen BS. (2008). Neurobiological and clinical effects of the antidepressant tianeptine. CNS Drugs, 22(1): 15-26. 2008. ↩︎
Sharp T, et al. (2017). 5-HT neurons and the dorsal raphe: Translational relevance for neuropsychiatric disorders. Brain Research, 1663: 32-47. 2017. ↩︎
Lowry CA, et al. (2008). Serotonergic systems and neuropsychiatric diseases. Annual Review of Neuroscience, 31: 265-295. 2008. ↩︎